The JAK2 gene is a protein-coding gene of the Janus kinase family. It plays a role in cellular signaling. Evidence notes connections between this gene and some medical conditions. Variations in this ...

In a multicenter phase I trial, oral TG101348 was administered once a day to patients with high- or intermediate-risk primary or post–polycythemia vera/essential thrombocythemia myelofibrosis. The ...

JAK2 belongs to the Janus family of cytoplasmic tyrosine kinases (JAK1–JAK3, TYK2) and functions as a crucial mediator of signaling for hematopoietic cytokines and hormones such as erythropoietin (Epo ...

Please provide your email address to receive an email when new articles are posted on . Riedlinger and colleagues assessed clinical sequencing data on 2,030 solid tumors examined at Rutgers University ...

Chronic myelogenous leukemia (CML) patients treated with imatinib mesylate (IM) become drug resistant by mutations within the kinase domain of Bcr–Abl, and by other changes that cause progression to ...

QIAGEN announced that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all ...

March 16, 2009 — A Janus kinase 2 (JAK2) gene mutation that increases susceptibility to several myeloproliferative neoplasms (MPNs) is the focus of 3 studies published online March 15 in Nature ...

JAK2-unmutated erythrocytosis has a variety of etiologies, and identifying the underlying cause may prove helpful in cases where it is secondary to another condition such as polycythemia vera. The ...

Onyx to provide an additional $20 million in funding for advancement of SB1518 and SB1578. S*BIO and Onyx Pharmaceuticals expanded their development collaboration and option and license ...

Six-month Phase IIa clinical trial results presented at the 2010 ACR/ARHP Annual Scientific Meeting demonstrate that INCB28050 improved ACR scores in patients inadequately treated with DMARDS and ...

Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. Methods: We screened for the presence of the ...

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), ...